Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases

A Meta-Analysis

Amarnath Marthi, Killian Donovan, Richard Haynes, David C. Wheeler, Colin Baigent, Christopher M. Rooney, Martin J. Landray, Sharon Moe, Jun Yang, Lisa Holland, Romina Di Giuseppe, Annet Bouma-de Krijger, Borislava Mihaylova, William G. Herrington

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased risk of cardiovascular disease in patients with CKD. Methods We identified prospective studies reporting associations between FGF-23 concentration and risk of cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each outcome and scaled to a comparison of the top versus bottom third of the baseline FGF-23 concentration, and the results aggregated. Results Depending on the assay used, median FGF-23 concentrations were 43–74 RU/ml and 38–47 pg/ml in 17 general population cohorts; 102–392 RU/ml in nine cohorts of patients with CKD not requiring dialysis; and 79–4212 RU/ml and 2526–5555 pg/ml in eight cohorts of patients on dialysis. Overall, comparing participants in the top and bottom FGF-23 concentration thirds, the summary RRs (95% confidence intervals [95% CIs]) were 1.33 (1.12 to 1.58) for myocardial infarction, 1.26 (1.13 to 1.41) for stroke, 1.48 (1.29 to 1.69) for heart failure, 1.42 (1.27 to 1.60) for cardiovascular mortality, and 1.70 (1.52 to 1.91) for all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, was 1.52 (95% CI, 1.28 to 1.79). When studies were ordered by average differences in FGF-23 concentration between the top and bottom thirds, there was no trend in RRs across the studies. Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.

Original languageEnglish (US)
Pages (from-to)2000-2013
Number of pages14
JournalJournal of the American Society of Nephrology
Volume29
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Meta-Analysis
Cardiovascular Diseases
Odds Ratio
Mortality
Dialysis
Confidence Intervals
fibroblast growth factor 23
Heart Failure
Stroke
Myocardial Infarction
Prospective Studies
Population

ASJC Scopus subject areas

  • Nephrology

Cite this

Marthi, A., Donovan, K., Haynes, R., Wheeler, D. C., Baigent, C., Rooney, C. M., ... Herrington, W. G. (2018). Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology, 29(7), 2000-2013. https://doi.org/10.1681/ASN.2017121334

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases : A Meta-Analysis. / Marthi, Amarnath; Donovan, Killian; Haynes, Richard; Wheeler, David C.; Baigent, Colin; Rooney, Christopher M.; Landray, Martin J.; Moe, Sharon; Yang, Jun; Holland, Lisa; Di Giuseppe, Romina; Bouma-de Krijger, Annet; Mihaylova, Borislava; Herrington, William G.

In: Journal of the American Society of Nephrology, Vol. 29, No. 7, 01.07.2018, p. 2000-2013.

Research output: Contribution to journalArticle

Marthi, A, Donovan, K, Haynes, R, Wheeler, DC, Baigent, C, Rooney, CM, Landray, MJ, Moe, S, Yang, J, Holland, L, Di Giuseppe, R, Bouma-de Krijger, A, Mihaylova, B & Herrington, WG 2018, 'Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis', Journal of the American Society of Nephrology, vol. 29, no. 7, pp. 2000-2013. https://doi.org/10.1681/ASN.2017121334
Marthi, Amarnath ; Donovan, Killian ; Haynes, Richard ; Wheeler, David C. ; Baigent, Colin ; Rooney, Christopher M. ; Landray, Martin J. ; Moe, Sharon ; Yang, Jun ; Holland, Lisa ; Di Giuseppe, Romina ; Bouma-de Krijger, Annet ; Mihaylova, Borislava ; Herrington, William G. / Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases : A Meta-Analysis. In: Journal of the American Society of Nephrology. 2018 ; Vol. 29, No. 7. pp. 2000-2013.
@article{6ea4c891b777442893041437ded5f54c,
title = "Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis",
abstract = "Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased risk of cardiovascular disease in patients with CKD. Methods We identified prospective studies reporting associations between FGF-23 concentration and risk of cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each outcome and scaled to a comparison of the top versus bottom third of the baseline FGF-23 concentration, and the results aggregated. Results Depending on the assay used, median FGF-23 concentrations were 43–74 RU/ml and 38–47 pg/ml in 17 general population cohorts; 102–392 RU/ml in nine cohorts of patients with CKD not requiring dialysis; and 79–4212 RU/ml and 2526–5555 pg/ml in eight cohorts of patients on dialysis. Overall, comparing participants in the top and bottom FGF-23 concentration thirds, the summary RRs (95{\%} confidence intervals [95{\%} CIs]) were 1.33 (1.12 to 1.58) for myocardial infarction, 1.26 (1.13 to 1.41) for stroke, 1.48 (1.29 to 1.69) for heart failure, 1.42 (1.27 to 1.60) for cardiovascular mortality, and 1.70 (1.52 to 1.91) for all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, was 1.52 (95{\%} CI, 1.28 to 1.79). When studies were ordered by average differences in FGF-23 concentration between the top and bottom thirds, there was no trend in RRs across the studies. Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.",
author = "Amarnath Marthi and Killian Donovan and Richard Haynes and Wheeler, {David C.} and Colin Baigent and Rooney, {Christopher M.} and Landray, {Martin J.} and Sharon Moe and Jun Yang and Lisa Holland and {Di Giuseppe}, Romina and {Bouma-de Krijger}, Annet and Borislava Mihaylova and Herrington, {William G.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1681/ASN.2017121334",
language = "English (US)",
volume = "29",
pages = "2000--2013",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases

T2 - A Meta-Analysis

AU - Marthi, Amarnath

AU - Donovan, Killian

AU - Haynes, Richard

AU - Wheeler, David C.

AU - Baigent, Colin

AU - Rooney, Christopher M.

AU - Landray, Martin J.

AU - Moe, Sharon

AU - Yang, Jun

AU - Holland, Lisa

AU - Di Giuseppe, Romina

AU - Bouma-de Krijger, Annet

AU - Mihaylova, Borislava

AU - Herrington, William G.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased risk of cardiovascular disease in patients with CKD. Methods We identified prospective studies reporting associations between FGF-23 concentration and risk of cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each outcome and scaled to a comparison of the top versus bottom third of the baseline FGF-23 concentration, and the results aggregated. Results Depending on the assay used, median FGF-23 concentrations were 43–74 RU/ml and 38–47 pg/ml in 17 general population cohorts; 102–392 RU/ml in nine cohorts of patients with CKD not requiring dialysis; and 79–4212 RU/ml and 2526–5555 pg/ml in eight cohorts of patients on dialysis. Overall, comparing participants in the top and bottom FGF-23 concentration thirds, the summary RRs (95% confidence intervals [95% CIs]) were 1.33 (1.12 to 1.58) for myocardial infarction, 1.26 (1.13 to 1.41) for stroke, 1.48 (1.29 to 1.69) for heart failure, 1.42 (1.27 to 1.60) for cardiovascular mortality, and 1.70 (1.52 to 1.91) for all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, was 1.52 (95% CI, 1.28 to 1.79). When studies were ordered by average differences in FGF-23 concentration between the top and bottom thirds, there was no trend in RRs across the studies. Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.

AB - Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased risk of cardiovascular disease in patients with CKD. Methods We identified prospective studies reporting associations between FGF-23 concentration and risk of cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each outcome and scaled to a comparison of the top versus bottom third of the baseline FGF-23 concentration, and the results aggregated. Results Depending on the assay used, median FGF-23 concentrations were 43–74 RU/ml and 38–47 pg/ml in 17 general population cohorts; 102–392 RU/ml in nine cohorts of patients with CKD not requiring dialysis; and 79–4212 RU/ml and 2526–5555 pg/ml in eight cohorts of patients on dialysis. Overall, comparing participants in the top and bottom FGF-23 concentration thirds, the summary RRs (95% confidence intervals [95% CIs]) were 1.33 (1.12 to 1.58) for myocardial infarction, 1.26 (1.13 to 1.41) for stroke, 1.48 (1.29 to 1.69) for heart failure, 1.42 (1.27 to 1.60) for cardiovascular mortality, and 1.70 (1.52 to 1.91) for all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, was 1.52 (95% CI, 1.28 to 1.79). When studies were ordered by average differences in FGF-23 concentration between the top and bottom thirds, there was no trend in RRs across the studies. Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure–response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.

UR - http://www.scopus.com/inward/record.url?scp=85049396542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049396542&partnerID=8YFLogxK

U2 - 10.1681/ASN.2017121334

DO - 10.1681/ASN.2017121334

M3 - Article

VL - 29

SP - 2000

EP - 2013

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -